Libre Duo Glucose-Ketone Sensor to Launch in December
The new monitoring device will be available to U.S. patients in December 2026 with new insurance coverage starting next year.
Updated on Oct. 21, 2026 in Diabetes
Live Poll
Do you feel new medical devices are making diabetes management more affordable for your household?
Abbott is set to launch its new Libre Duo glucose-ketone sensor in the United States in December 2026. This device offers a new dual-monitoring option for patients managing diabetes, with updated payer coverage taking effect early next year.
Why it matters
The introduction of a combined glucose and ketone monitoring system aims to improve clinical safety by providing real-time data to help patients and providers identify and prevent diabetic ketoacidosis. The rollout is scheduled to coincide with updated insurance formulary coverage starting in 2027.
Abbott received FDA de novo clearance for the Libre Duo in August 2026 based on its ability to monitor ketone levels. While the system is designed to provide dual-tracking capabilities, the long-term impact on glycemic control remains an area of ongoing clinical interest.
The players
Abbott
A global healthcare company that produces medical devices, including continuous glucose monitoring systems for diabetes management.
FDA
The federal agency responsible for protecting public health by regulating the safety and efficacy of medical devices.
The details
The Libre Duo system utilizes sensor technology to continuously measure both glucose and ketone levels. By monitoring ketones, the device provides an additional safety layer for users to recognize when levels rise, which is a key indicator for potential diabetic ketoacidosis. This dual-monitoring approach allows users to track their metabolic data more comprehensively than glucose-only sensors.
Timeline
May 2026: Abbott received the CE Mark for the sensor.
August 2026: Abbott received FDA de novo clearance.
Fall 2026: International launch of the sensor.
December 2026: U.S. launch of the Libre Duo.
January 1, 2027: New payer formulary coverage goes into effect.
Health Landscape
The introduction of the Libre Duo marks a shift toward more integrated metabolic monitoring within the standard of care for diabetes. It builds upon the established market presence of the FreeStyle Libre glucose monitoring system by adding ketone sensing to standard metabolic tracking.
Patients who regularly track ketone levels for safety may find this dual-monitoring device helpful, but should verify insurance benefits before the January 2027 coverage changes. It is worth discussing with your doctor whether dual-metric monitoring is appropriate for your specific health needs.
The takeaway
The Libre Duo sensor provides a new option for individuals needing to track both glucose and ketone levels to manage diabetes risks. If you are interested in this technology, consult your physician or endocrinologist to determine if this monitoring system fits your existing management plan.
What happens next
Payer formulary coverage for the Libre Duo system is scheduled to change effective January 1, 2027.
Further reading
For more information on managing your care, visit the Diabetes section of our site.
Source note: This article includes information reported by MassDevice.
Live Poll
Do you feel new medical devices are making diabetes management more affordable for your household?
